Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis
Value in Health · 2023
DOI: 10.1016/j.jval.2023.01.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2023. Verfasst von Leila G Lackey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Decision Support and Analysis Staff, Office of Program and Strategic Analysis, Center for Drug Evaluation and Research, Food and Drug Administration,…. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Quantitative benefit-risk assessment (qBRA) is a structured process to evaluate the benefit-risk balance of treatment options to support decision making. The ISPOR qBRA Task Force was recently established to provide recommendations for the design, conduct, and reporting of qBRA. This report presents a hypothetical case study illustrating how to apply the Task Force's recommendations toward a qBRA to inform the benefit-risk assessment of brodalumab at the time of initial marketing approval. The qBRA evaluated 2 dosing regimens of brodalumab (210 mg or 140 mg twice weekly) compared with weight-based dosing of ustekinumab and placebo. METHODS: We followed the 5 steps recommended by the Task Force. Attributes included treatment response (≥75% improvement in Psoriasis Area and Severity Index), suicidal ideation and behavior, and infections. Performance data were drawn from pivotal clinical trials of brodalumab. The qBRA used multicriteria decision analysis and preference weights from a hypothetical discrete choice experiment. Sensitivity analyses examined the robustness of benefit-risk ranking to uncertainty in clinical effect and preference estimates, consideration of a subgroup (nail psoriasis), and the maintenance phase of treatment (52 weeks instead of 12). RESULTS: Results from this hypothetical qBRA suggest that brodalumab 210 mg had a more favorable benefit-risk profile compared with ustekinumab and placebo. Ranking of brodalumab compared with ustekinumab was dependent on brodalumab's dose. Sensitivity analyses demonstrated robustness of benefit-risk ranking to uncertainty in clinical effect and preference estimates, as well as choice of attributes and length of follow-up. CONCLUSION: This case study demonstrates how to implement the ISPOR Task Force's good practice recommendations on qBRA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Decision Support and Analysis Staff, Office of Program and Strategic Analysis, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Electronic address: leila.lackey@fda.hhs.gov.
- Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
- Erasmus School of Health Policy and Management & Erasmus Choice Modelling Center, Rotterdam, The Netherlands.
- School of Health and Related Research, University of Sheffield, Sheffield, England, UK.
- Global R&D Epidemiology, Janssen R&D, Titusville, NJ, USA.
- Manchester Centre for Health Economics, School of Health Sciences, The University of Manchester, Manchester, England, UK.
Zitieren
APA
Lackey, L. G., Ng, X., Veldwijk, J., Thokala, P., Levitan, B., Payne, K., Ho, M., & Tervonen, T. (2023). Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis. Value in Health. https://doi.org/10.1016/j.jval.2023.01.018
Vancouver
Lackey LG, Ng X, Veldwijk J, Thokala P, Levitan B, Payne K, et al. Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis. Value in Health. 2023. doi:10.1016/j.jval.2023.01.018
BibTeX
@article{Lackey2023,
author = {Lackey, Leila G and Ng, Xinyi and Veldwijk, Jorien and Thokala, Praveen and Levitan, Bennett and Payne, Katherine and Ho, Martin and Tervonen, Tommi},
title = {Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis},
journal = {Value in Health},
year = {2023},
doi = {10.1016/j.jval.2023.01.018}
}
EUVIMED